Carina S. Pinheiro et al., J <strong>Vaccines</strong> Vaccin <strong>2013</strong>, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference on<strong>Vaccines</strong> & VaccinationJuly 29-31, <strong>2013</strong> Embassy Suites Las Vegas, NV, USAVaccination with enzymatically cleaved GPI-anchored proteins from schistosoma mansoniinduces protection against challenge infectionCarina S. Pinheiro 1,2 , Vicente P. Martins 1,2,3 , Barbara C. P. Figueiredo 1,2 , Natan R. G. Assis 1,2 , Suellen B. Morais 1,2 , Marcelo V. Caliari 4 ,Vasco Azevedo 3 , WilliamCastro-Borges 5 , R. AlanWilson 6 and Sergio C. Oliveira 1, 21Departamento de Bioquímica, Imunologia do Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil2Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais (INCT-DT), Brazil3Departamento de Biologia Geral do Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil4Departamento de Patologia Geral do Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil5Departamento Ciências Biológicas, Universidade Federal de Ouro Preto, Brazil6Centre for Immunology & Infection, Department of Biology, University of York, UKThe flatworm Schistosoma mansoni is a blood fluke parasite that causes schistosomiasis, a debilitating disease that occursthroughout the developing world. Current schistosomiasis control strategies are mainly based on chemotherapy, but manyresearchers believe that the best long-term strategy to control schistosomiasis is through immunization with an antischistosomiasisvaccine combined with drug treatment. In the search for potential vaccine candidates, numerous tegument antigens have beenassessed. As the major interface between parasite and mammalian host, the tegument plays crucial roles in the establishmentand further course of schistosomiasis. Herein, we evaluated the potential of a GPI fraction, containing representative moleculeslocated on the outer surface of adult worms, as vaccine candidate. Immunization of mice with GPI-anchored proteins induceda mixed Th1/Th2 type of immune response with production of IFN-γ and TNF-α, and low levels of IL-5 into the supernatant ofsplenocyte cultures. The protection engendered by this vaccination protocol was confirmed by 42% reduction in worm burden,45% reduction in eggs per gram of hepatic tissue, 29% reduction in the number of granulomas per area, and 53% reduction inthe granuloma fibrosis. Taken together, the data herein support the potential of surface-exposed GPI-anchored antigens from theS.mansoni tegument as vaccine candidate.carinaspinheiro@yahoo.com.brJ <strong>Vaccines</strong> Vaccin <strong>2013</strong>ISSN: 2157-7560, JVV an open access journal<strong>Vaccines</strong>-<strong>2013</strong>July 29-31, <strong>2013</strong>Volume 4 Issue 5Page 144
Dhrubajyoti Nag, J <strong>Vaccines</strong> Vaccin <strong>2013</strong>, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference on<strong>Vaccines</strong> & VaccinationJuly 29-31, <strong>2013</strong> Embassy Suites Las Vegas, NV, USAImmunogenicity and protective efficacy of oral heat-killed multi-serotype Shigella (HKMS)vaccine in rabbit modelDhrubajyoti NagNational Institute of Cholera and Enteric Diseases, IndiaBacillary dysentery caused by Shigella species, is a major cause of infant morbidity and mortality in developed as well asin developing countries. Now-a-days, we are approaching towards untreatable Shigellosis due to the global emergence ofmultidrug resistance which is increasing the importance of an anti-dysentery vaccine. Till date no suitable Shigella vaccineis available for public health use. The immune responses against Shigella species are serotype-specific and there are differentserotypes of Shigella species which demands an immunization strategy that will include multiple vaccine strains to provideprotection against multiple serotypes. In our study, we evaluated the protective efficacy and immune response of heat-killedcocktail form (HKMS) of six Shigella strains (S. dysenteriae 1, S. flexneri 2a, S. flexneri 3a, S. flexneri 6, S. boydii and S. sonnei)in rabbit model. Rabbits were immunized with 10 7 heat-killed Shigella strains four times with one week interval on 0, 7 th , 14 th& 21 st day and were challenged on the 28 th day with 10 9 organisms of wild type virulent Shigella strains. Immunized rabbits didnot develop shigellosis compare to the non-immunized rabbits. Serum IgG and IgA titers showed exponential rise during oralimmunization. Antibody in Lymphocyte Supernatant (ALS) assay, Cytokine assay and Immunoblotting against both whole celllysates and lypopolysaccharide have demonstrated a strong protective immune response following the oral immunization ofHKMS; thus justifying the potential of HKMS to become a “non-living” vaccine candidate against shigellosis in our future.BiographyDhrubajyoti Nag has completed his graduation in Microbiology from University of Calcutta in 2009 and completed his post graduation in Biotechnologyfrom Jadavpur University in 2011. Now he is doing his Ph.D. under the guidance of Dr. Hemanta Koley, Scientist C, National Institute of Choleraand Enteric Diseases, India, under a project of Okayama University, Japan, entitled Development and evaluation of a heat killed multi-serotype oralShigella vaccine.nagdhrubajyoti@gmail.comJ <strong>Vaccines</strong> Vaccin <strong>2013</strong>ISSN: 2157-7560, JVV an open access journal<strong>Vaccines</strong>-<strong>2013</strong>July 29-31, <strong>2013</strong>Volume 4 Issue 5Page 145
- Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
- Page 3 and 4:
Medical SciencesISSNAddiction Resea
- Page 5 and 6:
Impact Factors (IF) and Index Coper
- Page 7 and 8:
111 th OMICS Group Conference3 rd I
- Page 9 and 10:
Journal of Clinical & Cellular Immu
- Page 11 and 12:
111 th OMICS Group Conference3 rd I
- Page 13 and 14:
111 th OMICS Group Conference3 rd I
- Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
- Page 17 and 18:
Immunology Summit-2013OMICS Group i
- Page 19 and 20:
Probiotics-2013OMICS Group is organ
- Page 21 and 22:
Virology-2013OMICS Group is organiz
- Page 23 and 24:
111 th OMICS Group Conference3 rd I
- Page 25 and 26:
Because of heightened awareness of
- Page 27 and 28:
111 th OMICS Group Conference3 rd I
- Page 29 and 30:
111 th OMICS Group Conference3 rd I
- Page 31 and 32:
111 th OMICS Group Conference3 rd I
- Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
- Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
- Page 37 and 38:
111 th OMICS Group Conference3 rd I
- Page 39 and 40:
Robert E. Sievers et al., J Vaccine
- Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
- Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
- Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
- Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
- Page 49 and 50:
Track 33: Novel Approaches in Desig
- Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
- Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
- Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
- Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
- Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
- Page 61 and 62:
Track 44: Vaccines against Infectio
- Page 63 and 64:
Haval Shirwan, J Vaccines Vaccin 20
- Page 65 and 66:
Rainer Fischer, J Vaccines Vaccin 2
- Page 67 and 68:
Alwyn Rapose, J Vaccines Vaccin 201
- Page 69 and 70:
Saroj Basak, J Vaccines Vaccin 2013
- Page 71 and 72:
Gisela Gonzalez, J Vaccines Vaccin
- Page 73 and 74:
Young Research ForumSession ChairPe
- Page 75 and 76:
Humberto Hernandez et al., J Vaccin
- Page 77 and 78:
Nisha Nair et al., J Vaccines Vacci
- Page 79 and 80:
Leow Yee et al., J Vaccines Vaccin
- Page 81 and 82:
Kaissar Tabynov et al., J Vaccines
- Page 83 and 84:
Teena Mohan et al., J Vaccines Vacc
- Page 85 and 86:
Track 5 & 95: Manufacturing, Produc
- Page 87 and 88:
Graham Clarke, J Vaccines Vaccin 20
- Page 89 and 90:
Obradovic Zarema et al., J Vaccines
- Page 91 and 92:
Abdur Razzaque Sarker et al., J Vac
- Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
- Page 95 and 96: 111 th OMICS Group Conference3 rd I
- Page 97 and 98: Regina Heidenreich et al., J Vaccin
- Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
- Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
- Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
- Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
- Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
- Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
- Page 111 and 112: Byung Chul Kim et al., J Vaccines V
- Page 113 and 114: STS. Chitradevi et al., J Vaccines
- Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
- Page 117 and 118: 111 th OMICS Group Conference3 rd I
- Page 119 and 120: Afshineh Latifynia et al., J Vaccin
- Page 121 and 122: Hemanta Koley et al., J Vaccines Va
- Page 123 and 124: Aleksandar Masic et al., J Vaccines
- Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
- Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
- Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
- Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
- Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
- Page 135 and 136: Mathan Periasamy et al., J Vaccines
- Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
- Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
- Page 141 and 142: 111 th OMICS Group Conference3 rd I
- Page 143: Birhanu Hurisa et al., J Vaccines V
- Page 147 and 148: Belachew Etana et al., J Vaccines V
- Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
- Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
- Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
- Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
- Page 157 and 158: Veronica Rainone et al., J Vaccines
- Page 159 and 160: Page 159
- Page 161 and 162: Previous111 th OMICS Group Conferen
- Page 163 and 164: PreviousWorld Congress and Expo onB